MOTS-c half-life & pharmacokinetics

Reported half-life

Approximately 0.5-2 hours plasma half-life after subcutaneous administration in rodent models; rapid plasma clearance similar to other small peptides. Tissue retention — particularly in skeletal muscle and adipose tissue — exceeds plasma half-life. Limited published pharmacokinetic data in larger species.

The half-life and pharmacokinetic profile of MOTS-c reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (research; standard route)
• Intraperitoneal injection (research models)
• Intramuscular injection (research, less common)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Mitochondrial-derived peptide (MDP); endogenous 16-amino-acid peptide encoded by the mitochondrial 12S rRNA region; AMPK and folate-cycle signalling modulator.

Mechanism context

Half-life interpretation depends on the underlying mechanism. MOTS-c acts as follows:

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid endogenous peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene — the first mitochondrial-derived peptide (MDP) discovered with established metabolic-regulatory function, identified by Pinchas Cohen and colleagues at the University of Southern California (Lee et al., Cell Metab 2015). Unlike most peptides encoded by the nuclear genome, MOTS-c is one of a small number of bioactive peptides whose primary genetic instructions reside in the mitochondrial genome — a discovery that has broader implications for understanding the mitochondrial-nuclear retrograde signalling that coordinates cellular energy status with broader physiology.

See the full MOTS-c research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.